Celiac Disease Leukopak

High-Yield LeukoCore Celiac Disease Leukopaks for Autoimmune Immunology Research

LeukoCore Celiac Disease Leukopak biospecimens are collected from IRB-consented donors clinically diagnosed with celiac disease through IRB-approved apheresis procedures. Each leukopak contains large quantities of peripheral blood mononuclear cells (PBMCs), making it suited to antigen-specific immune profiling, cytokine analysis, and drug development research in celiac disease. Cell counts and viability are reported per lot.

Why a Leukopak for Celiac Disease Research

Celiac disease is an autoimmune enteropathy triggered by dietary gluten in genetically susceptible people. The cellular immunology is unusually well defined, and it is precisely that definition which makes cell number the limiting factor — the population of interest is rare, and a leukopak is how you get enough of it.

• Susceptibility is almost entirely restricted to HLA-DQ2 and HLA-DQ8. Gluten peptides deamidated by tissue transglutaminase 2 bind these molecules with high affinity and are presented to gluten-specific CD4+ T cells, so donor HLA genotype is a first-order variable in any celiac T cell experiment.
• Gluten-specific CD4+ T cells circulate at very low frequency. Detecting and phenotyping them with HLA-DQ tetramers or antigen-specific assays requires far more cells than a standard venepuncture provides, which is the core rationale for apheresis-derived material.
• The disease is autoimmune because the antibody response targets a self antigen: autoantibodies against tissue transglutaminase 2, alongside antibodies to deamidated gliadin peptides, are the serological hallmark and the basis of clinical diagnosis.
• Intestinal damage is mediated by intraepithelial cytotoxic lymphocytes activated in an IL-15-rich environment through NK-type receptors, giving a defined innate-like effector arm alongside the CD4+ T cell response.
• Because pathology depends on continuing antigen exposure, gluten intake at the time of collection materially affects the frequency of circulating gluten-reactive cells — dietary status is a study design variable, not donor trivia.
• Therapeutic programmes in celiac disease target transglutaminase 2, gluten degradation, and antigen-specific tolerance induction, all of which require large numbers of primary patient cells with known HLA restriction for mechanistic and potency work.

Donor Stratification Available

• HLA typing, including DQ2 and DQ8 status, available on request for selected inventory
• Serology: anti-tissue transglutaminase IgA and deamidated gliadin peptide antibody status, current or normalised, where documented
• Biopsy-confirmed diagnosis and histological grade where recorded
• Dietary status at collection: gluten-free diet with duration, partial adherence, or gluten-containing diet
• Refractory or persistently symptomatic disease, and dermatitis herpetiformis where present
• Associated autoimmune conditions such as type 1 diabetes or autoimmune thyroid disease, and selective IgA deficiency
• Matched healthy controls available, including HLA-DQ2-positive non-celiac donors on request

Product Features

• Research Use Only (RUO) human celiac disease leukopaks
• Clinically confirmed celiac disease donors
• High cell yield for large-scale studies
• Processed and shipped within 24 hours of collection
• Fresh or cryopreserved options available
• IRB-approved and ethically sourced
• Infectious disease testing
• HLA-A typing
• Screen donors with LeukoLot™

De-identified Donor Data

• Verified celiac disease diagnosis from healthcare providers
• Donor demographics: age, sex assigned at birth, race/ethnicity
• Self-reported medication history and allergies
• Dietary status and serology where available
• Relevant clinical data (if available)

Applications

• HLA-DQ tetramer staining and gluten-specific CD4+ T cell detection and phenotyping
• Antigen-specific proliferation, cytokine, and tolerance-induction assays
• Immune cell characterisation and immunophenotyping in celiac disease
• Isolation of T cell, B cell, NK cell, and monocyte subsets at scale from a single donor
• Therapeutic development, screening, and potency assays for celiac-directed candidates
• T cell receptor repertoire sequencing of gluten-reactive populations
• Multi-omics studies including single-cell RNA sequencing
• Comparative autoimmunity research alongside other autoimmune donor cohorts

Other Celiac Disease Specimen Types

• Celiac Disease Serum
• Celiac Disease Plasma
• Celiac Disease Whole Blood
• Celiac Disease PBMC
• Celiac Disease CD4+ T Cells
• Celiac Disease CD3+ T Cells
• Celiac Disease Bulk Plasma

Compliance and Quality Assurance

• Collected under IRB oversight with donor e-consent (21 CFR Part 11 compliant)
• HIPAA-compliant handling of donor information
• Rigorous donor screening and documentation

Ordering & Customization

Celiac disease leukopak samples are available fresh or cryopreserved. For pricing and current availability, or if you need a different condition, visit our human leukopak page to browse other disease-state options and live stock status. For international shipping or regulatory documentation, please contact learnmore@sanguinebio.com to confirm regional compliance and shipping availability.